Greg Dietsch

Biography

Gregory N Dietsch, PhD, DABT currently serves as Vice President of Research at VentiRx Pharmaceuticals. Prior to joining VentiRx, Dr. Dietsch was Vice President of Preclinical Sciences at ICOS Corporation, where he built and directed the pharmacology, drug metabolism, pathology and toxicology departments that supported ICOS Research and Clinical development programs. Dietsch has over 20 years industry experience in the discovery and clinical development of novel therapeutic agents. He has worked on programs in multiple therapeutic areas that include: multiple sclerosis, psoriasis, pulmonary arterial hypertension, chronic obstructive pulmonary disease, acute respiratory distress syndrome, oncology, immune-oncology, stroke, pancreatitis, sepsis, interstitial cystitis, erectile dysfunction and pain. Dr. Dietsch has advance more than twenty therapeutic agents, including monoclonal antibodies, recombinant proteins, natural products and traditional small molecule drugs, from research phase into clinical development. Three of these programs resulted in marketed products, that include: Cialis®, Thelin®, and Zydelig®, A native of Washington State, Dr. Dietsch completed his undergraduate and Masters Degrees at Washington State University in Microbiology. He is trained as a cellular immunologist and received his PhD in Microbiology/Immunology from the Oregon Health Sciences University in Portland Oregon. He is also trained as a toxicologist and is a Diplomat of the American Board of Toxicology (DABT).

Research Interest

Pharmacology, Drug Metabolism, Pathology and Toxicology